Description: Standard BioTools, previously known as Fluidigm, is driven by a bold vision – unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the Company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies that help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy.
Home Page: www.fluidigm.com
LAB Technical Analysis
2 Tower Place
South San Francisco,
CA
94080
United States
Phone:
650 266 6000
Officers
| Name | Title |
|---|---|
| Mr. Vikram Jog | Chief Financial Officer |
| Dr. Michael Egholm Ph.D. | Pres, CEO & Director |
| Dr. Stephen R. Quake D.phil., Ph.D. | Co-Founder & Chairman of Advisory Board |
| Mr. Hanjoon Kim | Chief Operating Officer |
| Mr. Andrew Quong Ph.D. | Chief Science Officer |
| Mr. Peter DeNardo | Investor Relations |
| Mr. Rafael Aguirre-Sacasa | Acting Gen. Counsel |
| Mark Spearman | Sr. Director of Corp. Communications |
| Ms. Angela Peters | Chief HR Officer |
| Dr. David A. King Ph.D. | Sr. VP of Global R&D |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8691 |
| Price-to-Sales TTM: | 0.9876 |
| IPO Date: | 2003-07-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 615 |